FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077825239> ?p ?o ?g. }

• W2077825239 endingPage "1751" @default.
• W2077825239 startingPage "1742" @default.
• W2077825239 abstract "This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors. Small tumors of the anal margin were not included since they were treated by surgical excision only. Among the 101 patients were 74 women and 27 men with a median age of 62 (range, 26-84) years. T categories (International Union against Cancer) were T1 (15), T2 (36), T3 (34), and T4 (16). Seventy-one patients had no evidence of nodal disease, whereas 30 presented with involved regional nodes. Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy. Lesions greater than 5 cm received an additional boost by interstitial or external radiation depending on circumferential extension of the residual tumor. All patients were scheduled for simultaneous chemotherapy with two cycles of 5-fluorouracil at a dose of 1000 mg/m (2)/day as 120 hours of continuous intravenous infusion on Days 1 to 5 and 29 to 33 and mitomycin C at 10 mg/m (2)/day on Days 1 and 29. Median follow-up time was was 7.5 (range, 1-16) years.Overall survival and colostomy-free survival rates for patients with anal canal cancer were 75 percent and 87 percent at five years, respectively. Patients with anal margin cancer had a less favorable outcome with five-year-overall and colostomy-free survival rates of 54 percent and 69 percent, respectively. After correction for imbalance between anal canal and anal margin tumors, i.e., exclusion of T1 tumors of the anal canal, difference in overall survival remained significant (73 percent vs. 54 percent, P = 0.01). Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival. Initial tumor response at six weeks (P = 0.03) was predictive for colostomy-free survival.With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level. However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable." @default.
• W2077825239 created "2016-06-24" @default.
• W2077825239 creator A5028499415 @default.
• W2077825239 creator A5030506578 @default.
• W2077825239 creator A5062068471 @default.
• W2077825239 creator A5071080657 @default.
• W2077825239 creator A5080216358 @default.
• W2077825239 creator A5091305170 @default.
• W2077825239 date "2005-09-01" @default.
• W2077825239 modified "2023-10-10" @default.
• W2077825239 title "Tumor Site Predicts Outcome After Radiochemotherapy in Squamous-Cell Carcinoma of the Anal Region: Long-Term Results of 101 Patients" @default.
• W2077825239 cites W1804130247 @default.
• W2077825239 cites W1853092317 @default.
• W2077825239 cites W1908777919 @default.
• W2077825239 cites W1947979503 @default.
• W2077825239 cites W1974234666 @default.
• W2077825239 cites W1978414580 @default.
• W2077825239 cites W1990718815 @default.
• W2077825239 cites W1992918344 @default.
• W2077825239 cites W1994934546 @default.
• W2077825239 cites W1996218351 @default.
• W2077825239 cites W1998218507 @default.
• W2077825239 cites W2006040276 @default.
• W2077825239 cites W2012642018 @default.
• W2077825239 cites W2013628426 @default.
• W2077825239 cites W2016538482 @default.
• W2077825239 cites W2026811255 @default.
• W2077825239 cites W2044216592 @default.
• W2077825239 cites W2052910344 @default.
• W2077825239 cites W2058869441 @default.
• W2077825239 cites W2059601249 @default.
• W2077825239 cites W2062681066 @default.
• W2077825239 cites W2069640589 @default.
• W2077825239 cites W2092407000 @default.
• W2077825239 cites W2119713502 @default.
• W2077825239 cites W2137960802 @default.
• W2077825239 cites W2163596952 @default.
• W2077825239 cites W2335500033 @default.
• W2077825239 cites W4253473049 @default.
• W2077825239 cites W4293241248 @default.
• W2077825239 cites W776995397 @default.
• W2077825239 cites W86702416 @default.
• W2077825239 doi "https://doi.org/10.1007/s10350-005-0098-5" @default.
• W2077825239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15991058" @default.
• W2077825239 hasPublicationYear "2005" @default.
• W2077825239 type Work @default.
• W2077825239 sameAs 2077825239 @default.
• W2077825239 citedByCount "69" @default.
• W2077825239 countsByYear W20778252392012 @default.
• W2077825239 countsByYear W20778252392013 @default.
• W2077825239 countsByYear W20778252392014 @default.
• W2077825239 countsByYear W20778252392015 @default.
• W2077825239 countsByYear W20778252392016 @default.
• W2077825239 countsByYear W20778252392017 @default.
• W2077825239 countsByYear W20778252392018 @default.
• W2077825239 countsByYear W20778252392019 @default.
• W2077825239 countsByYear W20778252392021 @default.
• W2077825239 countsByYear W20778252392022 @default.
• W2077825239 countsByYear W20778252392023 @default.
• W2077825239 crossrefType "journal-article" @default.
• W2077825239 hasAuthorship W2077825239A5028499415 @default.
• W2077825239 hasAuthorship W2077825239A5030506578 @default.
• W2077825239 hasAuthorship W2077825239A5062068471 @default.
• W2077825239 hasAuthorship W2077825239A5071080657 @default.
• W2077825239 hasAuthorship W2077825239A5080216358 @default.
• W2077825239 hasAuthorship W2077825239A5091305170 @default.
• W2077825239 hasConcept C121608353 @default.
• W2077825239 hasConcept C126322002 @default.
• W2077825239 hasConcept C126894567 @default.
• W2077825239 hasConcept C141071460 @default.
• W2077825239 hasConcept C2776694085 @default.
• W2077825239 hasConcept C2777546739 @default.
• W2077825239 hasConcept C2779840525 @default.
• W2077825239 hasConcept C2780035688 @default.
• W2077825239 hasConcept C2780120127 @default.
• W2077825239 hasConcept C2780140570 @default.
• W2077825239 hasConcept C2780456651 @default.
• W2077825239 hasConcept C2781074409 @default.
• W2077825239 hasConcept C2781171867 @default.
• W2077825239 hasConcept C2910643260 @default.
• W2077825239 hasConcept C509974204 @default.
• W2077825239 hasConcept C523026621 @default.
• W2077825239 hasConcept C526805850 @default.
• W2077825239 hasConcept C71924100 @default.
• W2077825239 hasConceptScore W2077825239C121608353 @default.
• W2077825239 hasConceptScore W2077825239C126322002 @default.
• W2077825239 hasConceptScore W2077825239C126894567 @default.
• W2077825239 hasConceptScore W2077825239C141071460 @default.
• W2077825239 hasConceptScore W2077825239C2776694085 @default.
• W2077825239 hasConceptScore W2077825239C2777546739 @default.
• W2077825239 hasConceptScore W2077825239C2779840525 @default.
• W2077825239 hasConceptScore W2077825239C2780035688 @default.
• W2077825239 hasConceptScore W2077825239C2780120127 @default.
• W2077825239 hasConceptScore W2077825239C2780140570 @default.
• W2077825239 hasConceptScore W2077825239C2780456651 @default.
• W2077825239 hasConceptScore W2077825239C2781074409 @default.
• W2077825239 hasConceptScore W2077825239C2781171867 @default.
• W2077825239 hasConceptScore W2077825239C2910643260 @default.

• next